Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.
【저자키워드】 COVID-19, Immunosuppression, rituximab, Case report, convalescent antibodies, double filtration plasmapheresis, coagulation biomarkers, hypercoagulability, 【초록키워드】 Randomized controlled trial, SARS-CoV-2, coronavirus, pandemic, therapy, severe COVID-19, antibody, monoclonal antibody, rituximab, Chemotherapy, anti-SARS-CoV-2 antibody, B-cell lymphoma, outbreak, viral disease, Neutralizing, respiratory, convalescent, disease, anti-CD20, Donor, Evidence, infusion, COVID-19 patient, evidence of, observation, antiviral immune response, acute respiratory syndrome, diffuse large B-cell lymphoma, treat, passive antibody therapy, Administered, filtration, effective, benefit, infused, Passive, 【제목키워드】 Plasmapheresis, Effect,